ARS Pharmaceuticals (SPRY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.63
- Estimate
- -$0.49
- Surprise
- -27.7%
- Revenue (period 2026-06-30)
- $33.7M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
ARS Pharmaceuticals (SPRY) reported a wider loss than forecast — adjusted EPS of -$0.63 against the -$0.49 estimate (a 27.7% shortfall).
Coverage in the report window
- Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s — benzinga, 2026-08-14
- Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket — benzinga, 2026-08-14
- ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates SPRY Hold at 5.5/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -27.7% surprise compares with a -3.2% four-quarter average. Next scheduled report: 2027-03-09.
What argues against it
- Concentration risk — Pipeline: neffy
- DATA_ISSUE: analyst_target_implausible (raw $17.00 vs price $3.59 — ratio 4.7×). Rejected, falling back to technical TP.
- Market cap $391M below $400M minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.59
- Price target
- $4.35
- Stop
- $3.34
- Upside to target
- +21.2%
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
SPRY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $391.1M
- P/E (fwd)
- -4.5
- 52-week range
- $2.44–$13.15
- Off 52-week high
- 72.7%
- RSI (14)
- 48
- Volume vs avg
- 1.38×
- Score today
- 5.5/10